ABC | Volume 111, Nº4, Octuber 2018

Short Editorial Izar & Fonseca Predictors of family recruiting Arq Bras Cardiol. 2018; 111(4):585-586 References This is an open-access article distributed under the terms of the Creative Commons Attribution License 1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478–90a. 2. Brænne I, Kleinecke M, Reiz B, Graf E, Strom T, Wieland T, et al. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J HumGenet 2016;24(2):191-7. 3. Abul-Husn NS, Manickam K, Jones LK, Wright EA, Hartzel DN, Gonzaga- Jauregui C, et al. Genetic identification of familial hypercholesterolemia withinasingleU.S.healthcaresystem.Science.2016;354(6319):piiaaf7000. 4. Santos RD, Gagliardi AC, Xavier HT, Casella Filho A, Araujo DB, Cesena FY, et al. [First BrazilianGuidelines for Familial Hypercholesterolemia]. Arq Bras Cardiol. 2012;99(2 Suppl 2):1–28. 5. Perez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135(22):2133–44. 6. Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67(11):1278–85. 7. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet. 2004;66(6):483-7. 8. Santos RD, Bourbon M, Alonso R, Cuevas A, Vásquez-Cárdenas A, Pereira AC, et al. Clinical andmolecular aspects of familial hypercholesterolemia in Ibero-American countries. J Clin Lipidol. 2016;11(1):160–6. 9. Henderson R, O’Kane M, McGilligan V, Watterson S. The genetics and screeningoffamilialhypercholesterolaemia.JBiomedSci.2016Apr16;23:39. 10. Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38(23):1832–9. 11. Lázaro P, Pérez de Isla L, Watts GF, Alonso R, Norman R, Muñiz O, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260–71. 12. Silva PRS, Jannes CE, Oliveira TGM, Gómez LMG, Krieger JE, Santos RD, et al. Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia. ArqBras Cardiol. 2018; 111(4):578-584. 13. KheraAV,WonHH,PelosoGM,awsonKS,BartzTM,DengX,etal.Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol .2016;67(22):2578–89. 14. Kassner U, Wuhle-Demuth M, Missala I,Humphries SE, Steinhagen- Thiessen E, Demuth I. Clinical utility gene card for: hyper- lipoproteinemia, type II. Eur J HumGenet. 2014;22(7) doi:10.10338/ejhg.2013.271. Epub 2013 Nov 20 586